Earnings ·
Biohaven Ltd. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $137.3…
BHVNBiohaven Ltd.
Biohaven Ltd. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $137.3 million, or $0.91 per share, compared to a net loss of $198.1 million in the prior year period. Research and development expenses decreased to $100.8 million from $184.4 million due to strategic reprioritization and lower one-time milestone payments. The company reported cash, cash equivalents, marketable securities, and restricted cash totaling approximately $270.5 million as of June 30, 2026. Clinically, Biohaven initiated a pivotal Phase 3 study for BHV-1300 in Graves' disease and plans to initiate a pivotal Phase 3 trial for BHV-1400 in IgA nephropathy during the second half of 2026. The company also announced new clinical data for its oncology candidate BHV-1530 and completed enrollment in a Phase 2 obesity study for taldefgrobep alfa. Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare and common diseases.